Sandra Porcile Rojas-Caro
Director/Board Member bei RIPLEY CORP S.A.
Profil
Sandra Porcile Rojas-Caro is an Independent Director at Ripley Corp.
SA since 2020.
She was previously the Chief Medical Officer at Spyre Therapeutics, Inc. and Gemini Therapeutics, Inc. She also served as VP-Clinical Research & Exploratory Development at Synageva BioPharma Corp.
from 2013 to 2014.
Dr. Rojas-Caro holds an undergraduate and doctorate degree from Pontificia Universidad Católica de Chile.
Aktive Positionen von Sandra Porcile Rojas-Caro
| Unternehmen | Position | Beginn |
|---|---|---|
| RIPLEY CORP S.A. | Director/Board Member | 01.01.2020 |
Ehemalige bekannte Positionen von Sandra Porcile Rojas-Caro
| Unternehmen | Position | Ende |
|---|---|---|
| NEUBASE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 28.10.2022 |
| GEMI THER | Chief Tech/Sci/R&D Officer | - |
| SPYRE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
| SYNAGEVA BIOPHARMA CORP | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Sandra Porcile Rojas-Caro
| Pontificia Universidad Católica de Chile | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| SPYRE THERAPEUTICS, INC. | Health Technology |
| RIPLEY CORP S.A. | Retail Trade |
| NEUBASE THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
Gemini Therapeutics, Inc.
 Gemini Therapeutics, Inc. BiotechnologyHealth Technology Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. It is developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration. The company was founded by Johanna Seddon, Paul Barlow and Andrew Herbert on March 3, 2015 and is headquartered in Cambridge, MA. | Health Technology |
